Halozyme Therapeutics (HALO) Inventory (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Inventory data on file, last reported at $155.5 million in Q1 2026.

• Inventory for Q1 2026 came in at $155.5 million, down 5.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $155.5 million (down 5.7% YoY), and the FY2025 annual result was $176.5 million, up 24.4% from the prior year.
• Inventory eased to $155.5 million in Q1 2026 per HALO's latest filing, from $176.5 million in the prior quarter.
• Over five years, Inventory peaked at $185.8 million in Q3 2025 and troughed at $47.8 million in Q1 2022.
• A 5-year average of $135.9 million and a median of $132.4 million in 2023 frame the typical range for Inventory.
• The sharpest annual moves came in 2022 and 2023: Inventory slipped 18.14% in 2022, then jumped 125.12% in 2023.
• A 5-year view of Inventory shows it stood at $100.1 million in 2022, then grew by 27.44% to $127.6 million in 2023, then climbed by 11.17% to $141.9 million in 2024, then rose by 24.4% to $176.5 million in 2025, then retreated by 11.9% to $155.5 million in 2026.
• Business Quant data shows HALO's Inventory at $155.5 million in Q1 2026, $176.5 million in Q4 2025, and $185.8 million in Q3 2025.